02.27.24 -- Shaping A Digitally Enabled Commercialization Road Map

Accelerating the production of your viral-vector based therapy requires understanding the strategies and cost-efficiencies available to address the viral vector manufacturing shortage.

About 85% of industry leaders and managers have had some exposure to AI. Delve into the state of AI adoption experienced throughout 2023 and where the industry is headed concerning digital tool usage.

Find the right solutions for your organization to comply with and maintain product quality and safety despite conflicting cGMP FDA 21 CFR Part 210 and 211 cleanroom and BMBL requirements.

Explore a modified synthetic sgRNA that allows you to achieve efficient, multigene knockout in primary human resting CD4+ T cells.

Maintaining a cleanroom facility that remains safe for your workers – and where the therapeutics they produce remain safe for patients – can ease your compliance concerns.

Review a showcase of a high throughput robust analysis for nucleic acid integrity and size assessment of mRNA-LNP samples using a multi-capillary system and purity and integrity analysis kit.

Despite the momentum of the RNA-LNP therapeutic market, significant manufacturing challenges remain. However, the right mixing could solve three of these key challenges regarding instrumentation.

Are you searching for a better way to calculate growth rate? Explore a new approach that performs the rate calculations using a simple method to correct for volume changes.

Learn how PCR-based mycoplasma detection assays can provide a rapid alternative to culturing with comparable sensitivity, specificity, and species range that can facilitate quick decision-making.